Tamoxifen and breast cancer incidence among women with inherited mutations in brca1 and brca2 national surgical adjuvant breast and bowel project (nsabp-p1) breast cancer prevention trial

JAMA

Volumn 286, Issue 18, 2001, Pages 2251-2256

  King, Mary Claire ^a   Wieand, Sam ^b   Hale, Kathryn ^a   Lee, Ming ^a   Walsh, Tom ^a   Owens, Kelly ^a   Tait, Jonathan ^a   Ford, Leslie ^c   Dunn, Barbara K ^c   Costantino, Joseph ^b   Wickerham, Lawrence ^b   Wolmark, Norman ^b   Fisher, Bernard ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0035861037     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.18.2251     Document Type: Article

References (41)

1. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project PI Study
2. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
3. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
4. Identification of the breast cancer susceptibility gene BRCA2
5. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
6. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes
7. Incidence of BRCA1/2 germ line alterations in a high-risk cohort participating in a phase II chemoprevention trial
8. Tumour biological features of BRCA1-induced breast and ovarian cancer
9. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different?
10. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA 1 or BRCA2 mutations and sporadic cases
11. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
12. Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1
13. Base-calling of automated sequencer traces using Phred, II: Error probabilities
14. Base-calling of automated sequencer traces using Phred, I: Accuracy assessment
15. PolyPhred: Automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing
16. SeqHelp: A program to analyze molecular sequences utilizing common computational resources
17. Consed: A graphical tool for sequence finishing
18. A polymorphic stop codon in BRCA2
19. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women
20. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases
21. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
22. Breast and ovarian cancer risks among women with BRCA1 and BRCA2 mutations in the New York Breast Cancer Study
23. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer
24. BRCA-associated breast cancer in young women
25. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status in breast cancers in Ashkenazi Jewish women
26. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
27. Survival in hereditary breast cancer associated with germline mutations of BRCA2
28. BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations
29. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: Specific BRCA1 mutations and pathological characteristics
30. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population-based study
31. Linkage of early-onset familial breast cancer to chromosome 17q21
32. Cancer risks in BRCA2 mutation carriers
33. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer
34. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation
35. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
36. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
37. Tamoxifen for early breast cancer: An overview of the randomised trials
38. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study